{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:58:41Z","timestamp":1760061521366,"version":"3.40.4"},"reference-count":16,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.jpba.2014.03.039","type":"journal-article","created":{"date-parts":[[2014,4,4]],"date-time":"2014-04-04T20:36:39Z","timestamp":1396643799000},"page":"33-38","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Development and validation of UFLC\u2013MS\/MS method for determination of bosentan in rat plasma"],"prefix":"10.1016","volume":"97","author":[{"given":"Alptug","family":"Atila","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Ozturk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yucel","family":"Kadioglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zekai","family":"Halici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Didar","family":"Turkan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammed","family":"Yayla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harun","family":"Un","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2014.03.039_bib0005","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0022-3565(25)22357-6","article-title":"Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist","volume":"270","author":"Clozel","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jpba.2014.03.039_bib0010","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.pharmthera.2005.08.012","article-title":"Endothelin receptor antagonists","volume":"110","author":"Motte","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jpba.2014.03.039_bib0015","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.clinthera.2010.01.004","article-title":"Warfarin and bosentan interaction in a patient with pulmonary hypertension secondary to bilateral pulmonary emboli","volume":"32","author":"Spangler","year":"2010","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jpba.2014.03.039_bib0020","unstructured":"TracleerTM (bosentan) Product Information, Actelion Pharmaceuticals. Available from <http:\/\/www.tracleer.com\/content\/pdf\/Tracleer-Full-Prescribing-Information>, 2011."},{"key":"10.1016\/j.jpba.2014.03.039_bib0025","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0090-9556(24)15230-0","article-title":"Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects","volume":"27","author":"Weber","year":"1999","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jpba.2014.03.039_bib0030","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2133\/dmpk.DMPK-10-RG-113","article-title":"Pharmacokinetics of bosentan in routinely treated Japanese pediatric patients with pulmonary arterial hypertension","volume":"26","author":"Taguchi","year":"2011","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.jpba.2014.03.039_bib0035","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/bdd.671","article-title":"Mechanisms responsible for the altered pharmacokinetics of Bosentan: analysis utilizing rats with bile duct ligation-induced liver dysfunction","volume":"30","author":"Horiuchi","year":"2009","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.jpba.2014.03.039_bib0040","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1007\/s00216-011-5641-8","article-title":"High-resolution mass spectrometry for integrated qualitative and quantitative analysis of pharmaceuticals in biological matrices","volume":"402","author":"Hopfgartner","year":"2012","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2014.03.039_bib0045","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jpba.2012.06.027","article-title":"Development of an SPE-LC-MS\/MS method for simultaneous quantification of bosentan and its active metabolite hydroxybosentan in human plasma to support a bioequivalence study","volume":"70","author":"Parekha","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2014.03.039_bib0050","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0021-9673(95)00331-G","article-title":"Determination of an endothelin receptor antagonist in human plasma by narrow-bore liquid chromatography and ionspray tandem mass spectrometry","volume":"712","author":"Lausecker","year":"1995","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2014.03.039_bib0055","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0378-4347(00)00386-8","article-title":"Simultaneous determination of bosentan and its three major metabolites in various biological matrices and species using narrow bore liquid chromatography with ion spray tandem mass spectrometric detection","volume":"749","author":"Lausecker","year":"2000","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2014.03.039_bib0060","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jchromb.2011.12.012","article-title":"Development and validation of a fully automated online human dried blood spot analysis of bosentan and its metabolites using the Sample Card And Prep DBS System","volume":"885\u2013886","author":"Ganz","year":"2012","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2014.03.039_bib0065","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1046\/j.1365-2125.2002.01608.x","article-title":"Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole","volume":"53","author":"van Giersbergen","year":"2002","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2014.03.039_bib0070","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/(SICI)1096-9888(199601)31:1<69::AID-JMS264>3.0.CO;2-Q","article-title":"Fragmentation of Bosentan\u00ae(Ro 47-0203) in ionspray mass spectrometry after collision-induced dissociation at low energy: a case of radical fragmentation of an even-electron ion","volume":"31","author":"Hopfgartnert","year":"1996","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.jpba.2014.03.039_bib0075","unstructured":"U.S. Food And Drug Administration, Guidance for Industry Bioanalytical Method Validation. Available from: <http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM070107.pdf>, 2001."},{"key":"10.1016\/j.jpba.2014.03.039_bib0080","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/bmc.857","article-title":"Development and validation of gas chromatography\u2013mass spectroscopy method for determination of prilocaine HCl in human plasma using internal standard methodology","volume":"21","author":"Kadioglu","year":"2007","journal-title":"Biomed. Chromatogr."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708514001666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708514001666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T07:49:47Z","timestamp":1746172187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708514001666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":16,"alternative-id":["S0731708514001666"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2014.03.039","relation":{},"ISSN":["0731-7085"],"issn-type":[{"type":"print","value":"0731-7085"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of UFLC\u2013MS\/MS method for determination of bosentan in rat plasma","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2014.03.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}